PolarityTE: Jumps after positive initial data from diabetic foot ulcer study

RegenETP,

10/05/2021 14:07

** Shares of regenerative tissue developer PolarityTE Inc
 PTE.O  jump 19.6% to $1.16 premarket - among top pct gainers
across U.S. exchanges 
    ** PTE reports preliminary data from a clinical trial
showing its tissue-based product candidate SkinTE combined with
standard-of-care to treat diabetic foot ulcers met the main and
secondary goals  urn:newsml:reuters.com:*:nBw90Qv8nav
    ** Says 70% of patients receiving SkinTE plus
standard-of-care had wound closure at 12 weeks vs 34% of
patients receiving standard-of-care alone, which was the trial's
main goal
    ** Percent Area Reduction - a measure of healing and trial's
secondary goal- was significantly greater for the SkinTE plus
standard-of-care treatment group vs standard-of-care alone, PTE
says
     ** SkinTE is a product derived from a patient's own skin
intended for the repair, reconstruction, replacement or
supplementation of skin tissue
    ** Stock had gained 43.3% YTD, as of last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))